Kelsey Roelofs1, Matthew P Larocque2, Albert Murtha3, Ezekiel Weis1,4. 1. Department of Ophthalmology and Visual Sciences, University of Alberta, Edmonton, Alberta, Canada. 2. Division of Medical Physics, Department of Oncology, University of Alberta, Edmonton, Alberta, Canada. 3. Department of Oncology, University of Alberta, Edmonton, Alberta, Canada. 4. Department of Surgery, University of Calgary, Calgary, Alberta, Canada.
Abstract
BACKGROUND/AIMS: To evaluate a treatment regimen for radiation papillopathy. METHODS: This is a prospective noncomparative interventional case series of patients who developed radiation papillopathy after plaque brachytherapy for uveal melanoma. Treatment consisted of intravitreal bevacizumab (IVB) (1.25 mg in 0.05 mL) at the time of diagnosis, and 1 week later, intravitreal triamcinolone (IVK) (2.00 mg in 0.05 mL). One month later, patients again received both IVB and IVK. Patients were then switched to monotherapy with monthly IVB until the papillopathy resolved. RESULTS: Eleven patients developed radiation papillopathy, with 9 receiving treatment. On multivariate analysis, total radiation dose to the optic nerve was the only significant predictor of papillopathy (p = 0.005). Four of nine patients presented with a significant decline in visual acuity (VA) at the time of diagnosis of papillopathy. In all 4, significant improvement was documented following treatment. Five patients did not present with a decrease in VA, and in this group, 80% remained stable with treatment. CONCLUSIONS: In this series, patients who had a precipitous drop in VA at the time of diagnosis of radiation papillopathy returned to baseline VA following this treatment algorithm. This protocol was effective at maintaining stability of VA in 80% of those who developed papillopathy but did not present with an acute drop in VA.
BACKGROUND/AIMS: To evaluate a treatment regimen for radiation papillopathy. METHODS: This is a prospective noncomparative interventional case series of patients who developed radiation papillopathy after plaque brachytherapy for uveal melanoma. Treatment consisted of intravitreal bevacizumab (IVB) (1.25 mg in 0.05 mL) at the time of diagnosis, and 1 week later, intravitreal triamcinolone (IVK) (2.00 mg in 0.05 mL). One month later, patients again received both IVB and IVK. Patients were then switched to monotherapy with monthly IVB until the papillopathy resolved. RESULTS: Eleven patients developed radiation papillopathy, with 9 receiving treatment. On multivariate analysis, total radiation dose to the optic nerve was the only significant predictor of papillopathy (p = 0.005). Four of nine patients presented with a significant decline in visual acuity (VA) at the time of diagnosis of papillopathy. In all 4, significant improvement was documented following treatment. Five patients did not present with a decrease in VA, and in this group, 80% remained stable with treatment. CONCLUSIONS: In this series, patients who had a precipitous drop in VA at the time of diagnosis of radiation papillopathy returned to baseline VA following this treatment algorithm. This protocol was effective at maintaining stability of VA in 80% of those who developed papillopathy but did not present with an acute drop in VA.
Authors: Carol L Shields; Hakan Demirci; Brian P Marr; Arman Mashayekhi; Vicktoria V Dai; Miguel A Materin; Jerry A Shields Journal: Retina Date: 2006 May-Jun Impact factor: 4.256
Authors: H Faghihi; R Roohipoor; S-F Mohammadi; K Hojat-Jalali; A Mirshahi; A Lashay; N Piri; Sh Faghihi Journal: Eur J Ophthalmol Date: 2008 Nov-Dec Impact factor: 2.597
Authors: Lauren A Dalvin; Christopher L Deufel; Kimberly S Corbin; Ivy A Petersen; Timothy W Olsen; Gavin W Roddy Journal: J Neuroophthalmol Date: 2021-11-11 Impact factor: 4.415
Authors: Dan Lin; Jiajiang Hu; Ke Wu; Kemi Feng; Xia Zhao; Qingqing Lu; Mingxue Ren; Junlin Cao; Ruru Liu; Mali Dai; Kaihui Nan; Yuqin Wang Journal: Drug Des Devel Ther Date: 2022-04-08 Impact factor: 4.162